Table 4 In vitro aerosol dispersion performance of co-SD TMC: Man as DPIs (n = 3, mean ± standard deviation).

From: Design and development of innovative microparticulate/nanoparticulate inhalable dry powders of a novel synthetic trifluorinated chalcone derivative and Nrf2 agonist

Inhaler device

Aerolizer

SD pump rate

25%

75%

100%

ED (%)

96.36 ± 0.78

100.42 ± 2.17

101.68 ± 2.07

FPF (%)

28.20 ± 4.31

5.61 ± 4.05

26.28 ± 3.64

RF (%)

74.38 ± 33.08

38.57 ± 16.78

79.40 ± 34.44

MMAD (µm)

3.56 ± 0.51

11.74 ± 0.70

5.31 ± 0.51

GSD

2.15 ± 0.10

3.00 ± 0.62

2.61 ± 1.03

Inhaler device

Neohaler

SD pump rate

25%

75%

100%

ED (%)

102.03 ± 0.45

89.56 ± 13.30

100.18 ± 1.98

FPF (%)

32.63 ± 3.82

7.32 ± 1.28

36.12 ± 1.67

RF (%)

71.30 ± 30.96

25.99 ± 11.32

79.38 ± 34.48

MMAD (µm)

4.56 ± 0.56

14.99 ± 1.96

5.07 ± 0.26

GSD

1.87 ± 0.24

2.49 ± 0.26

1.95 ± 0.07

Inhaler device

HandiHaler

SD pump rate

25%

75%

100%

ED (%)

91.43 ± 9.26

97.69 ± 0.79

92.53 ± 2.70

FPF (%)

28.54 ± 1.51

15.57 ± 0.62

38.75 ± 2.33

RF (%)

50.27 ± 21.82

41.43 ± 17.96

66.61 ± 28.88

MMAD (µm)

6.93 ± 0.63

9.44 ± 0.14

5.47 ± 0.10

GSD

2.69 ± 0.08

2.03 ± 0.02

2.08 ± 0.03

  1. ED emitted dose, FPF fine particle fraction, RF respirable fraction, MMAD mass median aerodynamic diameter, GSD geometric standard deviation.
Back to article page